Please login to the form below

Not currently logged in
Email:
Password:

radium Ra 223 dichloride

This page shows the latest radium Ra 223 dichloride news and features for those working in and with pharma, biotech and healthcare.

Xarelto leads the charge at Bayer

Xarelto leads the charge at Bayer

There were also gains for Eylea (aflibercept) for age-related macular degeneration (AMD) as well as prostate cancer drug Xofigo (radium Ra 223 dichloride) and Adempas (riociguat) for pulmonary artery hypertension.

Latest news

  • Eylea growth closes the gap with Lucentis Eylea growth closes the gap with Lucentis

    Combined sales of Bayer's five growth products - Eylea, pulmonary hypertension drug Adempas (riociguat), anticoagulant Xarelto (rivaroxaban) and cancer therapies Stivarga (regorafenib) and Xofigo (radium Ra 223 dichloride) - came in at

  • Bayer's Eylea cleared for wider use in Europe Bayer's Eylea cleared for wider use in Europe

    For the full year, revenues were up 5% to 42.2bn. The company's five most recently launched drugs - Eylea; anticoagulant Xarelto (rivaroxaban); cancer drugs Stivarga (regorafenib) and Xofigo (radium Ra ... 223 dichloride); and pulmonary hypertension

  • Personalised cancer medicines showcased in BBC investigation Personalised cancer medicines showcased in BBC investigation

    Astellas and Medivation's advanced prostate cancer drug Xtandi (enzalutamide) was highlighted being used with Bayer's Xofigo (Radium Ra 223 Dichloride) for an elderly patient with late-stage prostate cancer

  • Exelixis axes staff as lead cancer programme fails Exelixis axes staff as lead cancer programme fails

    already revitalised by the recent introductions of Zytiga, Xtandi and Bayer's radiopharmaceutical Xofigo (radium Ra 223 dichloride).

  • Bayer raises sales predictions for new pharma products Bayer raises sales predictions for new pharma products

    The new products - anticoagulant Xarelto (rivaroxaban), eye medicine Eylea (aflibercept), cancer drugs Stivarga (regorafenib) and Xofigo (radium Ra 223 dichloride) and pulmonary hypertension therapy Adempas (riociguat) - are now expected to add

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics